ReviewWomen's health (London, England)
Understanding migraine throughout a woman's life and the role of calcitonin gene-related peptide: A narrative review.
Review in Women's health (London, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Migraine in children and adolescents.Developmental medicine and child neurology · 2026Review
- Clinical characteristics of pure menstrual migraine and menstrually-related migraine: a cross-sectional online questionnaire study.BMC neurology · 2026Article
- Hormonal Contraceptives and Migraine Frequency and Severity in Women: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States.Frontiers in neurology · 2026Observational
- Tinnitus constancy and self-reported severe headache or migraine symptoms in peri- and postmenopausal women: a statistical modeling and machine learning analysis.European journal of medical research · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a common, chronic, and highly disabling neurological disorder that affects women at a higher rate than men. The frequency and severity of migraine varies throughout the stages of a woman's life. Fluctuations in sex hormones, notably estrogen, appear to influence susceptibility to migraine attacks. Unstable and declining levels of estrogen can predispose women to the onset of migraine attacks, whereas high and stable levels of estrogen can, under certain conditions, exert a protective effect. Calcitonin gene-related peptide (CGRP) signaling has emerged as a prominent mediator of migraine and is the target of several therapeutic advances in the acute and preventive treatment of migraine. Higher plasma CGRP levels are observed in women compared with men, indicating that CGRP and estrogen systems may be intertwined. The interaction of CGRP and estrogen may be a key driver in the susceptibility to migraine attacks. This review will explore migraine through the different reproductive stages of a woman's life: puberty and menstruation, pregnancy, and throughout the menopausal transition, with a focus on estrogen and its interplay with CGRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.